A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects With Major Depressive Disorder With Anxious Distress

Trial Profile

A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects With Major Depressive Disorder With Anxious Distress

Suspended
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs JNJ 42165279 (Primary)
  • Indications Anxiety disorders; Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 03 Mar 2017 Planned End Date changed from 1 Aug 2018 to 1 Jan 2019.
    • 31 Oct 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Aug 2018.
    • 19 Sep 2016 Planned End Date changed from 1 Mar 2018 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top